138 related articles for article (PubMed ID: 28025170)
1. Instability of C154Y variant of aldo-keto reductase 1C3.
Endo S; Takada S; Honda RP; Müller K; Weishaupt JH; Andersen PM; Ludolph AC; Kamatari YO; Matsunaga T; Kuwata K; El-Kabbani O; Ikari A
Chem Biol Interact; 2017 Oct; 276():194-202. PubMed ID: 28025170
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the major single nucleotide polymorphic variants of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase).
Detlefsen AJ; Wangtrakuldee P; Penning TM
J Steroid Biochem Mol Biol; 2022 Jul; 221():106121. PubMed ID: 35489629
[TBL] [Abstract][Full Text] [Related]
3. Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3.
Bukum N; Novotna E; Morell A; Hofman J; Wsol V
Chem Biol Interact; 2019 Apr; 302():101-107. PubMed ID: 30703376
[TBL] [Abstract][Full Text] [Related]
4. Human dehydrogenase/reductase SDR family member 11 (DHRS11) and aldo-keto reductase 1C isoforms in comparison: Substrate and reaction specificity in the reduction of 11-keto-C
Endo S; Morikawa Y; Kudo Y; Suenami K; Matsunaga T; Ikari A; Hara A
J Steroid Biochem Mol Biol; 2020 May; 199():105586. PubMed ID: 31926269
[TBL] [Abstract][Full Text] [Related]
5. Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment.
Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
Biochem Pharmacol; 2018 Oct; 156():22-31. PubMed ID: 30077642
[TBL] [Abstract][Full Text] [Related]
6. In situ proteolysis of an N-terminal His tag with thrombin improves the diffraction quality of human aldo-keto reductase 1C3 crystals.
Plavša JJ; Řezáčová P; Kugler M; Pachl P; Brynda J; Voburka Z; Ćelić A; Petri ET; Škerlová J
Acta Crystallogr F Struct Biol Commun; 2018 May; 74(Pt 5):300-306. PubMed ID: 29717998
[TBL] [Abstract][Full Text] [Related]
7. Significance of aldo-keto reductase 1C3 and ATP-binding cassette transporter B1 in gain of irinotecan resistance in colon cancer cells.
Matsunaga T; Okumura N; Saito H; Morikawa Y; Suenami K; Hisamatsu A; Endo S; Ikari A
Chem Biol Interact; 2020 Dec; 332():109295. PubMed ID: 33096057
[TBL] [Abstract][Full Text] [Related]
8. Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile.
Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
Arch Toxicol; 2018 Sep; 92(9):2845-2857. PubMed ID: 29992508
[TBL] [Abstract][Full Text] [Related]
9. Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
Pippione AC; Carnovale IM; Bonanni D; Sini M; Goyal P; Marini E; Pors K; Adinolfi S; Zonari D; Festuccia C; Wahlgren WY; Friemann R; Bagnati R; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2018 Apr; 150():930-945. PubMed ID: 29602039
[TBL] [Abstract][Full Text] [Related]
10. Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review.
Karunasinghe N; Masters J; Flanagan JU; Ferguson LR
Curr Cancer Drug Targets; 2017; 17(7):603-616. PubMed ID: 28359237
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Evaluation of the Reductase Activities of Human
Takano S; Fukami T; Ichida H; Suzuki K; Nakano M; Nakajima M
Drug Metab Dispos; 2023 Sep; 51(9):1188-1195. PubMed ID: 37344179
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a highly specific monoclonal antibody against human aldo-keto reductase AKR1C3.
Liu J; He P; Lin L; Zhao Y; Deng W; Ding H; Li Q; Wang Z
Steroids; 2019 Mar; 143():73-79. PubMed ID: 30639543
[TBL] [Abstract][Full Text] [Related]
13. AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Penning TM
Mol Cell Endocrinol; 2019 Jun; 489():82-91. PubMed ID: 30012349
[TBL] [Abstract][Full Text] [Related]
14. Availability of aldo-keto reductase 1C3 and ATP-binding cassette B1 as therapeutic targets for alleviating paclitaxel resistance in breast cancer MCF7 cells.
Matsunaga T; Horinouchi M; Saito H; Hisamatsu A; Iguchi K; Yoshino Y; Endo S; Ikari A
J Biochem; 2023 Mar; 173(3):167-175. PubMed ID: 36413758
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
16. Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study.
Gashaw I; Reif S; Wiesinger H; Kaiser A; Zollmann FS; Scheerans C; Grevel J; Piraino P; Seidel H; Peters M; Rottmann A; Rohde B; Arlt W; Hilpert J
Eur J Endocrinol; 2023 Jul; 188(7):578-591. PubMed ID: 37306288
[TBL] [Abstract][Full Text] [Related]
17. Reversal of Apalutamide and Darolutamide Aldo-Keto Reductase 1C3-Mediated Resistance by a Small Molecule Inhibitor.
Morsy A; Trippier PC
ACS Chem Biol; 2020 Mar; 15(3):646-650. PubMed ID: 32125151
[TBL] [Abstract][Full Text] [Related]
18. Role of Human Aldo-Keto Reductases in the Metabolic Activation of the Carcinogenic Air Pollutant 3-Nitrobenzanthrone.
Murray JR; Mesaros CA; Arlt VM; Seidel A; Blair IA; Penning TM
Chem Res Toxicol; 2018 Nov; 31(11):1277-1288. PubMed ID: 30406992
[TBL] [Abstract][Full Text] [Related]
19. Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand.
Karunasinghe N; Symes E; Gamage A; Wang A; Murray P; Zhu S; Goudie M; Masters J; Ferguson LR
PLoS One; 2019; 14(5):e0217373. PubMed ID: 31125365
[TBL] [Abstract][Full Text] [Related]
20. Aryl hydrocarbon receptor counteracts pharmacological efficacy of doxorubicin via enhanced AKR1C3 expression in triple negative breast cancer cells.
Yamashita N; Kanno Y; Saito N; Terai K; Sanada N; Kizu R; Hiruta N; Park Y; Bujo H; Nemoto K
Biochem Biophys Res Commun; 2019 Aug; 516(3):693-698. PubMed ID: 31253396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
